Business Context and Reporting Period
This Form 8-K Current Report was filed by Ultragenyx Pharmaceutical Inc. on January 30, 2019. The filing discloses a corporate governance event regarding the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The primary material change reported is the appointment of Shehnaaz Suliman, M.D., as a Class I director, effective January 30, 2019. Concurrent with this appointment, the Board size was fixed at nine directors, divided into three classes of three directors each. Dr. Suliman's term will expire at the 2020 annual meeting of stockholders.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, outlook, or management commentary regarding business operations. It details Dr. Suliman's professional background, including roles at Theravance Biopharma, Genentech, Gilead Sciences, and Lehman Brothers, and notes her status as a Rhodes Scholar. Regarding compensation, Dr. Suliman will receive standard non-employee director compensation and was granted a stock option to purchase 20,000 shares at an exercise price of $48.85. An indemnification agreement was also executed.
Investor Verification Checklist
- Verify the total number of directors on the Board is now nine.
- Confirm the exercise price of the stock option granted to Dr. Suliman matches the closing stock price of $48.85 on January 30, 2019.
- Review the Non-Employee Director Compensation Policy to understand the full scope of Dr. Suliman's compensation package.
- Check for any related party transactions involving Dr. Suliman, though the filing states none exist under Item 404(a).